Boswellia serrata (Indian Frankincense)

Boswellia serrata (Indian Frankincense)

Product Name: Босвеллия пильчатая, Boswellia serrata, Indischer Weihrauch, Incienso indio, Encens indien, اللبان الهندي, ขี้โกงอินเดีย, Hind olibanum, Инд босвеллия, Hind buxuri, Gûlgûn-e Hindî, Indiškas smilkalinis medis, Indijas vīraks, Індійський ладан, Hindistan buxuru, הלבונה ההודית

Synonyms: Босвеллия индийская, индийский ладан, смола босвеллии, босвеллия серрата; Indian frankincense, Salai, Salai guggul; Indischer Weihrauch, Indisches Weihrauchharz; Incienso indio, Salai; Encens indien, oliban indien; اللبان الهندي، صمغ بوزويليا؛ ขี้โกงอินเดีย, ยางบอสเวลเลีย

Used Parts: resin, bark, leaves, extracts, wood, seeds, essential oil, latex, aqueous extracts, alcohol tinctures, resin.

Main Indications for Use of Boswellia serrata: Osteoarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, bronchial asthma, psoriasis, chronic sinusitis, multiple sclerosis, malignant brain tumors, breast cancer, prostate cancer, diabetic nephropathy, neuropathic pain, prostatic hyperplasia, hyperlipidemia, systemic lupus erythematosus, obesity, chronic heart failure, acute pancreatitis, chronic hepatitis.

Use of Boswellia serrata in Mixtures and Complexes: Atopic dermatitis, irritable bowel syndrome, chronic bronchitis, gout, migraine, adenoiditis, seborrheic dermatitis, eczema, endometriosis, chronic prostatitis, atherosclerosis, arterial hypertension, vegetative dystonia, liver fibrosis.

Pharmacological Properties of Boswellia serrata: anti-inflammatory, analgesic, immunomodulating, antiproliferative, antioxidant, anti-angiogenic, hepatoprotective, antitumor, antimicrobial, neuroprotective, anti-edematous, antiseptic, bronchodilatory, 5-LOX inhibiting, spasmolytic, adaptogenic, antiallergic, vaso-strengthening, hypolipidemic, anti-asthmatic, antibacterial, antifungal, mild sedative.

Dosage of Pharmaceutical Forms — Boswellia serrata

Powder — Boswellia serrata

Indications (Powder): Osteoarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, chronic bronchitis, bronchial asthma, psoriasis, chronic sinusitis, malignant brain tumors, neuropathic pain, diabetic nephropathy, prostatic hyperplasia.

Standard Dosage (Powder): 2–3 grams of powder per day, divided into two doses — morning and evening, after meals, with warm water.

Enhanced Dosage (Powder): 4–5 grams per day in cases of severe inflammatory conditions: rheumatoid arthritis, ulcerative colitis, malignant brain tumors, and neuropathic pain.

Maximum Dosage (Powder): 6 grams per day for no more than 7 days in acute inflammatory episodes accompanied by pronounced pain and edema. Use should be agreed with the attending physician.

Preventive Dosage (Powder): 1 gram per day, once a day after meals. Recommended for chronic inflammatory diseases in remission: osteoarthritis, psoriasis, diabetic nephropathy, as well as for patients over 60 years of age and people with metabolic syndrome. Course — 21 days, repeated after one month.

Pediatric Dosage (Powder): For children over 12 years of age and with a body weight of at least 35 kg — 500 mg per day. For children under 12 years, scientific data on safety and efficacy are absent.

Contraindications (Powder): Individual intolerance, active gastric or duodenal ulcer, acute hepatitis. Scientifically confirmed data on contraindications during pregnancy, lactation, and in children under 12 years have not been registered.

Side Effects (Powder): In clinical practice, the following have been registered: nausea, heartburn, diarrhea, and skin rashes at dosages exceeding 6 grams per day.

Adjustment for Patient Body Weight: For body weight less than 60 kg — do not exceed 3 grams per day. For body weight more than 90 kg — an increase to 5 grams per day is possible if necessary.

Preparation Method (Powder): To prepare 100 grams of powder, take 120 grams of dried purified resin of Boswellia serrata. Soften the resin in a water bath at a temperature of 40–45 °C for 15 minutes, then quickly cool to room temperature and grind into a micropowder in a pharmaceutical mill to a fraction of less than 200 microns. Sift the resulting powder and package in an airtight container. The addition of anti-caking agents is not allowed.

Storage Conditions and Shelf Life (Powder): Store in a tightly closed light-proof glass container at a temperature of 5 to 25 °C, in a dry place, protected from direct light and electromagnetic sources. Shelf life — 18 months. After opening the package, use within 60 days.

Dry Extract — Boswellia serrata

Indications (Dry Extract): Osteoarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, malignant prostate tumors, chronic sinusitis, multiple sclerosis, diabetic nephropathy, chronic hepatitis, neuropathic pain.

Standard Dosage (Dry Extract): 250–300 milligrams of extract with a titration of boswellic acids of at least 65%, twice a day after meals.

Enhanced Dosage (Dry Extract): 500 milligrams of extract twice a day for severe forms of inflammatory bowel diseases, rheumatoid arthritis, tumors of the central nervous system and prostate.

Maximum Dosage (Dry Extract): 900 milligrams per day (in 3 doses) for no more than 10 days in a row, for pronounced symptoms of neuropathic pain, severe psoriatic arthritis, and multifocal joint inflammation.

Preventive Dosage (Dry Extract): 150 milligrams once a day after meals. Used for recurrent joint inflammations, type II diabetes mellitus, hyperlipidemia, and chronic hepatitis C in the inactive phase. Recommended for elderly patients, overweight individuals, and those with autoimmune pathologies. Course — 30 days, then a 2-week break.

Pediatric Dosage (Dry Extract): For children over 14 years of age with a body weight of at least 45 kg — up to 200 milligrams per day. For children under 14 years, scientifically confirmed safety data have not been registered.

Contraindications (Dry Extract): Hypersensitivity to boswellic acids, active gastric ulcer, acute pancreatitis. Scientifically confirmed data on contraindications during pregnancy, lactation, and in children under 14 years have not been registered.

Side Effects (Dry Extract): Rarely — gastralgia, nausea, mild flatulence, headache, allergic rashes when exceeding the dosage above 800 mg per day.

Adjustment for Patient Body Weight: Patients with body weight below 60 kg — no more than 300 milligrams per day. For body weight over 90 kg, an increase in dosage to 900 milligrams is allowed under medical supervision.

Preparation Method (Dry Extract): To obtain 100 grams of dry extract, take 500 grams of ground resin of Boswellia serrata. Pour 70% ethyl alcohol over the resin in a ratio of 1:10 and extract at a temperature of 50 °C for 6 hours in a water bath. Evaporate the filtrate to a thick mass, then dry in a vacuum drying oven at a temperature of 40 °C to obtain a dry residue. Grind the dry residue into powder, standardize by boswellic acid content (not less than 65%), and package in an airtight container.

Storage Conditions and Shelf Life (Dry Extract): Store in a tightly closed pharmaceutical package, in a dry, light-protected place, at a temperature of 5 to 25 °C. Avoid exposure to electromagnetic radiation. Shelf life — 2 years. After opening, use within 60 days.

Tincture — Boswellia serrata

Indications (Tincture): Osteoarthritis, rheumatoid arthritis, chronic bronchitis, bronchial asthma, chronic sinusitis, Crohn's disease, ulcerative colitis, neuropathic pain, psoriasis, chronic prostatitis, chronic hepatitis.

Standard Dosage (Tincture): 20 drops (approximately 1 ml) of tincture 3 times a day, diluted in 50 ml of water, after meals.

Enhanced Dosage (Tincture): 30 drops (1.5 ml) 3 times a day in cases of chronic inflammatory diseases of the respiratory and genitourinary system, psoriasis with a joint component, and irritable bowel syndrome.

Maximum Dosage (Tincture): 2 ml 3 times a day (total 6 ml per day) for no more than 7 days in exacerbation of chronic bronchitis, pronounced pain syndrome, or psoriatic arthritis.

Preventive Dosage (Tincture): 10 drops once a day in the morning after meals, diluted in a small amount of water. Recommended for patients with recurrent joint inflammations, bronchial hyperreactivity, allergic rhinitis, and chronic fatigue. Course — 30 days, repeated after 1 month.

Pediatric Dosage (Tincture): For children over 14 years — 10 drops 2 times a day. For children under 14 years, use is not recommended due to the content of ethyl alcohol.

Contraindications (Tincture): Alcohol dependence, epilepsy, severe liver lesions, pregnancy. Scientifically confirmed data on contraindications during lactation and in children under 14 years have not been registered; however, use is recommended to be avoided.

Side Effects (Tincture): When exceeding the dosage, a burning sensation in the stomach, dizziness, allergic reactions in the form of urticaria, and irritation of the pharyngeal mucosa are possible.

Adjustment for Patient Body Weight: For patients with body weight less than 60 kg — no more than 15 drops per single dose. For body weight over 90 kg — an increase in dosage to 30 drops per dose is permissible under medical supervision.

Preparation Method (Tincture): To prepare 100 ml of tincture, take 20 grams of ground Boswellia serrata resin and pour with 80 ml of 70% ethyl alcohol. The mixture is infused in a tightly closed dark glass bottle in a cool place for 10 days, shaken periodically. After infusion, the solution is filtered through multi-layer gauze or a paper filter. Store the finished tincture in a glass pharmacy container.

Storage Conditions and Shelf Life (Tincture): Store in a tightly closed dark glass container, at a temperature of 10 to 25 °C, away from light and heat sources. Protect from electromagnetic sources. Shelf life — 2 years. After opening, use within 90 days.

Oil Infusion — Boswellia serrata

Indications (Oil Infusion): Rheumatoid arthritis, osteoarthritis, psoriasis, eczema, chronic prostatitis, breast fibrosis, varicose veins of the lower extremities, neuropathic pain, inflammatory dermatoses, seborrheic dermatitis.

Standard Dosage (Oil Infusion): Externally 2 times a day: apply 3–5 ml of oil to the affected skin area or joint, rub in with light circular movements until completely absorbed.

Enhanced Dosage (Oil Infusion): Externally 3 times a day for pronounced joint inflammation, active phase of psoriasis with skin manifestations, severe neurodermatitis, and pain in the lumbar region or sacrum.

Maximum Dosage (Oil Infusion): Up to 6 ml per area up to 4 times a day for 5–7 days for severe pain, pronounced edema, and inflammation (including fibromyalgia and arthritis).

Preventive Dosage (Oil Infusion): Apply once a day (2–3 ml) to joints or problem skin areas for the prevention of exacerbations in chronic psoriasis, arthrosis, varicose veins, in the autumn-winter period, or after physical exertion. Course — 14–21 days.

Pediatric Dosage (Oil Infusion): For children from 6 years — externally once a day no more than 1 ml per area. Do not apply to mucous membranes, open wounds, or in children under 6 years. The child's sex does not matter.

Contraindications (Oil Infusion): Individual hypersensitivity, skin lesions with purulent discharge, allergic contact dermatitis in the active stage. Scientifically confirmed data on contraindications during pregnancy and lactation have not been registered, but when applied to the mammary glands — avoid getting on the nipple area.

Side Effects (Oil Infusion): Local skin redness, burning sensation, peeling, or allergic reaction with prolonged use of more than 21 days are possible.

Adjustment for Patient Body Weight: Adjustment is not required for external use; however, patients with a body weight below 40 kg are recommended to use with caution and use minimal volumes (up to 2 ml per session).

Preparation Method (Oil Infusion): To prepare 100 grams of infusion, take 20 grams of ground Boswellia serrata resin and 100 grams of organic cold-pressed coconut oil. Heat the resin in a water bath to 50 °C and pour with warm oil. Infuse for 48 hours at a temperature of 35–40 °C, shaking periodically. After infusion, filter the mixture through cotton cloth. Pour the resulting oil into a dark glass bottle.

Storage Conditions and Shelf Life (Oil Infusion): Store in a cool place at a temperature of 5 to 20 °C, away from direct light, in a dark glass bottle with a tight lid. Protect from EMI. Shelf life — 6 months. After opening, use within 60 days.

Ointment — Boswellia serrata

Indications (Ointment): Rheumatoid arthritis, osteoarthritis, lumbago, intercostal neuralgia, traumatic bruises, myositis, psoriasis with a joint component, eczema, trophic ulcers of the lower extremities, varicose veins, neuropathic pain.

Standard Dosage (Ointment): Apply 1–2 times a day in a thin layer to the affected skin area or joint area (2–4 grams of ointment per application), without rubbing, cover with cotton fabric.

Enhanced Dosage (Ointment): Apply 3 times a day for pronounced joint pain syndrome, acute inflammatory reactions in the spine area, psoriatic plaques, and soft tissue edema.

Maximum Dosage (Ointment): Up to 5 grams of ointment per application, up to 4 times a day, no more than 7 days in a row, for severe pain, neuralgia, and soft tissue fibrosis.

Preventive Dosage (Ointment): Apply once a day (2–3 grams of ointment) to joints, the spine, or skin in the area of chronic inflammation. Recommended for osteoarthritis, varicose veins, a tendency to dermatitis, and physical overload. Course — 14 days, repeat no more than once a month.

Pediatric Dosage (Ointment): Permissible for children over 10 years of age with a body weight of at least 30 kg, no more than 1 gram of ointment per day, once a day. For children under 10 years, use is not recommended due to the risk of skin hyperreactivity.

Contraindications (Ointment): Individual intolerance to ointment components, fresh wounds, purulent or infected skin lesions, and weeping eczema. Scientifically confirmed data on contraindications during pregnancy and lactation have not been registered; use with caution.

Side Effects (Ointment): Rarely: contact dermatitis, hyperemia, itching, and skin peeling when exceeding the dosage or with a long course.

Adjustment for Patient Body Weight: For patients with body weight below 60 kg — use the minimum dosage: no more than 2 grams of ointment per application. For body weight above 90 kg — an increase to 5 grams per application is permissible.

Preparation Method (Ointment): To prepare 100 grams of ointment, take: 20 grams of ground Boswellia serrata resin, 70 grams of coconut oil, 5 grams of beeswax, and 5 grams of natural lanolin. Infuse the resin in coconut oil at a temperature of 45 °C in a water bath for 24 hours, then strain. Combine the resulting oil extract with melted wax and lanolin, mix thoroughly until a homogeneous mass is obtained. Cool, package in an airtight pharmaceutical container.

Storage Conditions and Shelf Life (Ointment): Store in a tightly closed dark jar at a temperature of 5 to 15 °C, in a dry, light-protected place. Avoid overheating and electromagnetic exposure. Shelf life — 6 months. After opening, use within 30 days.

Cream — Boswellia serrata

Indications (Cream): Psoriasis, eczema, seborrheic dermatitis, allergic contact dermatitis, acne, telangiectasia, rosacea, scar changes of the skin, chronic inflammatory skin diseases.

Standard Dosage (Cream): Apply a thin layer 2 times a day (morning and evening) to clean and dry skin of the affected areas, 1–2 grams of cream per application.

Enhanced Dosage (Cream): Apply 3 times a day for pronounced inflammation, peeling, or itching characteristic of eczema, psoriasis, rosacea, and hypertrophic scars.

Maximum Dosage (Cream): Up to 3 grams per application, 4 times a day for exacerbation of inflammatory dermatoses and hyperkeratosis, for no more than 5 days in a row.

Preventive Dosage (Cream): Once a day (1 gram) on skin areas prone to recurrent inflammation, peeling, or hyperpigmentation. Recommended for chronic dermatitis, seborrhea, and after cosmetic procedures (laser, peeling). Course — 21 days.

Pediatric Dosage (Cream): Permitted from 6 years. For children from 6 to 12 years — apply once a day with 0.5 grams of cream. Do not apply to the face and mucous membranes without a doctor's recommendation.

Contraindications (Cream): Acute weeping eczema, individual intolerance, and active pustular skin processes. Scientifically confirmed data on contraindications during pregnancy and lactation have not been registered; external use with caution is permitted.

Side Effects (Cream): Short-term burning, redness, and a feeling of skin tightness when applied to damaged areas or in case of overdose.

Adjustment for Patient Body Weight: Adjustment is not required for external use. In children and adolescents, a half dosage is used.

Preparation Method (Cream): For 100 grams of cream: 20 grams of dry Boswellia serrata extract (65% boswellic acids), 40 grams of lavender hydrolate, 30 grams of coconut oil, 5 grams of an emulsifier based on glycerin and beeswax, and 5 grams of a natural plant-based preservative. Heat the oil phase (oil and wax) to 65 °C, and heat the aqueous phase (hydrolate with extract) separately to the same temperature. Combine with stirring, cool with constant whisking until a thick creamy texture is obtained. Package in airtight tubes.

Storage Conditions and Shelf Life (Cream): Store at a temperature of 5 to 15 °C, away from light and heating devices. Avoid storage near sources of EMI. Shelf life — 3 months. After opening the tube, use within 21 days.

Serum — Boswellia serrata

Indications (Serum): Hyperpigmentation, post-acne, inflammatory elements in acne, telangiectasia, initial stages of couperose, loss of skin elasticity, photoaging, micro-inflammatory changes in the epidermis in autoimmune and endocrine disorders.

Standard Dosage (Serum): Apply 1–2 times a day (morning and/or evening) with 3–5 drops to clean, slightly damp facial and neck skin. Avoid the area around the eyes.

Enhanced Dosage (Serum): Up to 7 drops 2 times a day for pronounced inflammatory elements, post-traumatic pigmentation, moderate acne, and decreased skin turgor.

Maximum Dosage (Serum): 10 drops per application (up to 20 drops per day), no more than 10 days in a row, for a pronounced inflammatory component, a combination of acne with pigmentation disorders and age-related skin changes.

Preventive Dosage (Serum): 3 drops once a day at night. Recommended for patients with hyperreactive skin, signs of photoaging, post-acne, as well as during the rehabilitation period after cosmetic procedures (laser, microdermabrasion, acid peels). Course — 28 days, then a 2-week break.

Pediatric Dosage (Serum): From 14 years — 1–2 drops once a day at night for juvenile acne. Under 14 years, not used due to the high concentration of active substances.

Contraindications (Serum): Individual intolerance, acute skin infections, herpetic rashes in the active phase, and damaged epidermis. Scientifically confirmed data on contraindications during pregnancy and lactation have not been registered; use only externally.

Side Effects (Serum): Rarely: temporary redness, burning sensation, peeling, and allergic reactions in sensitive skin and in case of overdose.

Adjustment for Patient Body Weight: Adjustment is not required, but with a body weight of less than 50 kg, it is recommended to start with minimal dosages (1–2 drops).

Preparation Method (Serum): For 100 ml of serum: 5 grams of dry Boswellia serrata extract (65% boswellic acids), 70 ml of distilled water, 20 ml of rosemary hydrolate, 2 ml of a natural preserving complex based on gluconolactone, and 3 ml of vegetable glycerin. Mix the components at a temperature of 25–30 °C until a homogeneous liquid is obtained, filter through a 0.2 μm bacterial filter. Pour into sterile dropper bottles.

Storage Conditions and Shelf Life (Serum): Store in the refrigerator at a temperature of 4 to 8 °C, in the original dark glass packaging, away from EMI and heat sources. Shelf life — 2 months. After opening, use within 21 days.

Onguent — Boswellia serrata

Indications (Onguent): Osteoarthritis, rheumatoid arthritis, trophic ulcers, psoriatic plaques with fissures, perianal fissures, chronic prostatitis (externally), inflammatory skin processes in the infiltration stage, and severe forms of seborrheic dermatitis.

Standard Dosage (Onguent): Apply 1–2 times a day to pre-cleansed skin areas, up to 4 grams per application, apply under a gauze bandage or leave open.

Enhanced Dosage (Onguent): Apply 3 times a day with 5 grams for infected fissures, inflamed psoriatic skin, deep eczematous lesions, including in the perianal area and inguinal folds.

Maximum Dosage (Onguent): 6 grams per application, no more than 4 times a day, for a maximum of 5 days for pronounced pain syndrome and hyperemia, and for local inflammations with an exudative component.

Preventive Dosage (Onguent): Once a day (2–3 grams) on skin areas prone to recurrent fissures, chronic inflammation, psoriasis, or eczema. Recommended for patients with dry and thinned skin, in old age. Course — 10–14 days, repeat once a month.

Pediatric Dosage (Onguent): Permitted from 10 years. Apply externally once a day with 1 gram. Do not allow use on extensive areas and on the face. The child's sex does not matter.

Contraindications (Onguent): Purulent skin infections, herpetic rashes, weeping eczema in the active phase, and individual intolerance. Scientifically confirmed contraindications during pregnancy and lactation have not been registered, but use is limited to small areas.

Side Effects (Onguent): Local irritation, edema, itching, and peeling with prolonged use or application to a wound surface.

Adjustment for Patient Body Weight: For patients with a body weight of less than 50 kg — do not exceed 3 grams per application. For patients over 90 kg, use of up to 6 grams is permissible, especially for lesions of large joints.

Preparation Method (Onguent): To prepare 100 grams of onguent, take: 30 grams of oil extract of Boswellia serrata, 40 grams of dehydrated lanolin, 20 grams of vegetable petroleum jelly, 5 grams of beeswax, and 5 grams of CO2 calendula extract. Mix all components at a temperature of 60 °C in a water bath, cool to 35 °C with stirring until a homogeneous dense texture is obtained. Package in pharmaceutical aluminum tubes or glass jars.

Storage Conditions and Shelf Life (Onguent): Store at a temperature of 5 to 15 °C, in an airtight package, away from light, heat, and electromagnetic radiation sources. Shelf life — 6 months. After opening, use within 30 days.

Emulgel — Boswellia serrata

Indications (Emulgel): Osteoarthritis, myalgia, traumatic sprains, lumbago, neuralgia of the trigeminal and sciatic nerves, tendinitis, chronic prostatitis (external application in projection), varicose veins with edema, localized psoriatic arthritis.

Standard Dosage (Emulgel): Apply to the affected skin area 2 times a day (morning and evening) with 2–4 grams per application, rub in with light movements until completely absorbed.

Enhanced Dosage (Emulgel): 3 times a day with 5 grams on joints, the lumbar area, calf muscles, in the presence of pain syndrome, edema, or nighttime stiffness.

Maximum Dosage (Emulgel): 6 grams per application, 4 times a day, for no more than 5 days for pronounced edema, inflammation, fibrosis, or inflammatory pain in deep tissues.

Preventive Dosage (Emulgel): Once a day (2 grams) in the evening, apply to the knees, lower back, elbow joints, or feet to prevent inflammation in chronic arthrosis, flat feet, static overload in the elderly, as well as in people who spend a lot of time on their feet. Course — 10–14 days, monthly.

Pediatric Dosage (Emulgel): Use from 12 years. Maximum — 1 gram of gel once a day. Avoid application to areas with thin skin (face, neck).

Contraindications (Emulgel): Individual intolerance, open wounds, inflammation with suppuration, and dermatoses in the exacerbation stage. Scientifically confirmed contraindications during pregnancy and lactation have not been registered, but it is recommended to avoid application to the abdomen and chest.

Side Effects (Emulgel): Skin redness, burning sensation, itching, and contact dermatitis, especially when applied to areas with impaired skin permeability.

Adjustment for Patient Body Weight: For patients with body weight up to 60 kg — no more than 3 grams per application. Over 90 kg — an increase in dosage to 6 grams is permissible.

Preparation Method (Emulgel): For 100 grams of emulgel: 20 grams of dry Boswellia serrata extract (standardized to 65% boswellic acids), 30 grams of hydrogel based on hyaluronic acid (1.5%), 30 grams of macadamia oil, 15 grams of emulsifier (cetearyl glucoside + glycerin), and 5 grams of witch hazel hydrolate. Heat the oil and aqueous phases to 60 °C, combine with stirring, cool to 30 °C. Introduce the extract and gel, whisk until a homogeneous gel-like structure is obtained. Package in pharmaceutical tubes or syringe dispensers.

Storage Conditions and Shelf Life (Emulgel): Store at a temperature of 8 to 15 °C in an airtight package, in a light-protected place, away from EMI. Shelf life — 3 months. After opening, use within 30 days.

Toxicity and Biosafety of Boswellia serrata

According to preclinical studies, Boswellia serrata resin has a high degree of biosafety. In an acute toxicological experiment on mice and rats with oral administration of Boswellia serrata extract standardized for boswellic acid content, the LD₅₀ value exceeds 2000 mg/kg of body weight, indicating low acute toxicity. No histopathological changes were detected in the tissues of the liver, kidneys, heart, and spleen.

In a 90-day subchronic toxicity study in rats receiving dry resin extract at doses up to 1000 mg/kg, no significant deviations in biochemical and hematological parameters were registered. Reproductive toxicity, mutagenicity, and carcinogenicity in standard Ames and Micronucleus tests have not been established.

Thus, Boswellia serrata is classified as a substance with a high biosafety profile when used in therapeutic doses.

Reference: https://www.ncbi.nlm.nih.gov/p...

Pharmacodynamics — Boswellia serrata

The pharmacodynamic properties of Boswellia serrata are determined by the complex action of boswellic acids — a group of pentacyclic triterpenoids contained in the resin of the plant. The most studied components are 11-keto-β-boswellic acid (KBA) and 3-O-acetyl-11-keto-β-boswellic acid (AKBA), which exhibit pronounced biological activity when affecting various physiological systems and cellular targets.

The key pharmacological effect is the anti-inflammatory action. It is realized through selective inhibition of the enzyme 5-lipoxygenase (5-LOX), responsible for the biosynthesis of leukotrienes — pro-inflammatory mediators involved in the modulation of cellular immune response. At the same time, boswellic acids have virtually no effect on the cyclooxygenase pathway (COX-1 and COX-2), which distinguishes them from most non-steroidal anti-inflammatory substances and reduces the risk of gastotoxicity. Inhibition of elastase and cathepsin G activity has also been recorded — proteases involved in the degradation of the intercellular matrix and the formation of inflammatory edema.

At the level of the immune system, a modulating effect on cytokine production has been noted. In particular, boswellic acids reduce the expression of pro-inflammatory interleukins (IL-1β, IL-6) and tumor necrosis factor-alpha (TNF-α), while regulating the activity of the nuclear transcription factor NF-κB. This action is accompanied by stabilization of neutrophil membranes and inhibition of their migration to the focus of inflammation. Normalization of immunoglobulin production and an effect on T-lymphocyte proliferation have also been noted.

At the level of the nervous system, antinociceptive and neuroprotective effects have been recorded, associated with the modulation of TRPV1 receptor activity, ion channels, and mediator transmission in peripheral nociceptors. In vivo studies show a decrease in lipid peroxidation in nervous tissue and normalization of the level of antioxidant enzymes — superoxide dismutase, catalase, and glutathione peroxidase.

For endocrine regulation, a mediated anti-androgenic and antiproliferative effect is characteristic due to the inhibition of 5-alpha-reductase and regulation of androgen receptor activity in target tissues. A modulating effect on the level of insulin-like growth factor and angiogenesis factors, in particular VEGF and MMP-9, has also been reported.

At the level of the skin and mucous membranes, boswellic acids demonstrate antioxidant, antibacterial, and keratoplastic effects. A decrease in metalloproteinase activity and normalization of the epidermal barrier function have been established. Local application contributes to the restoration of dermal structures, reduction of edema, and inflammatory infiltration.

With respect to the gastrointestinal tract, spasmolytic, secretory-modulating, and cytoprotective effects have been recorded. This is realized through a decrease in the level of prostaglandins E2 and leukotrienes in the mucous membrane, as well as through the stabilization of mast cells and a reduction in the production of histamine and serotonin in the intestinal wall.

The pharmacodynamics of boswellic acids also covers antioxidant and angiostatic spectrum, realized through suppression of lipid peroxidation, inhibition of NADPH-oxidase, and a decrease in the expression of ICAM-1 and VCAM-1 — endothelial adhesion molecules. This contributes to a reduction in oxidative stress at the level of the vascular wall and capillary permeability.

Thus, the action of Boswellia serrata covers several levels of regulation — local, tissue, and systemic. It affects key biochemical and immunological pathways, including lipoxygenase enzyme cascades, cytokine profiles, and antioxidant defense, which makes the pharmacodynamics of boswellia multi-level and balanced in terms of the spectrum of physiological action.

References:
https://www.ncbi.nlm.nih.gov/p...
https://www.sciencedirect.com/...
https://link.springer.com/arti...
https://pubchem.ncbi.nlm.nih.g...
https://www.tandfonline.com/do...

Pharmacokinetics — Boswellia serrata

The main active components of Boswellia serrata resin belong to the class of lipophilic pentacyclic triterpenoids with high molecular weight and pronounced tendency to bind to membrane structures. Pharmacokinetic properties are influenced by the form of administration and the degree of preliminary extraction — aqueous, alcoholic, oily, or dry.

With oral administration, boswellic acids are absorbed in the upper part of the small intestine, mainly in the lipophilic form. The absorption process is limited by low solubility in an aqueous medium, which requires the presence of dietary lipids to increase bioavailability. Studies confirm the participation of intestinal microflora in the partial metabolism of boswellic acids with the formation of less polar metabolites capable of systemic action. A small part of the compounds may undergo enzymatic transformation in the mucous membrane of the gastrointestinal tract.

After absorption, the active fractions are distributed mainly in tissues with a high lipid content — adipose tissue, cell membranes, synovial fluid, skin, and nervous components. Selective accumulation in foci of chronic inflammation and hypoxic tissues is noted, which is explained by active binding to the extracellular matrix and participation in the regulation of the mediator background. Penetration through the blood-brain barrier is limited; however, remote neuromodulating effects with long-term use are possible.

Metabolism is carried out primarily in the liver with the participation of monooxygenase and glucuronyltransferase enzyme systems. Metabolites undergo conjugation with glucuronic or sulfuric acid and are further transported to the excretory organs. The participation of microsomal oxidation in the transformation of acetyl and ketone groups is assumed, which reduces the pharmacological activity of derivatives.

Excretion of metabolites occurs primarily through the hepatobiliary route. A significant part of boswellic compounds is excreted with bile into the intestine, where reabsorption is possible (enteral circulation). The renal route of excretion is less significant, since most compounds are poorly soluble in water and are filtered in limited quantities. With transdermal and external use, absorption is minimal and is mainly limited to local tissues, without systemic load on detoxification organs. In the case of inhalation or sublingual administration, the active components exhibit accelerated pharmacokinetics with short-term action and an insignificant metabolic trace.

Cosmetic forms and external preparations exhibit pharmacokinetic activity at the level of the epidermis and upper layer of the dermis. With repeated applications, accumulation in the lipid layer of the skin may occur, which potentially prolongs the effect in chronic conditions. The participation of the skin in excretion is minimal and is determined only within the framework of local metabolic processes.

Thus, the pharmacokinetics of Boswellia serrata depends on the physicochemical properties of triterpenes, the method of administration, and the state of the mucous membranes and hepatic function of the patient. The main route of metabolism is hepatic, with biliary excretion and possible intestinal reabsorption, which determines the cumulative and prolonged action with course use.

References:
https://www.sciencedirect.com/...
https://www.ncbi.nlm.nih.gov/p...
https://www.mdpi.com/1420-3049...
https://www.tandfonline.com/do...

Mechanisms of Action and Scientific Rationale — Boswellia serrata

The pharmacological activity of Boswellia serrata is determined by the content of boswellic acids — lipophilic pentacyclic triterpenoids with the ability for multi-level biochemical action. One of the key mechanisms of action is the inhibition of the enzyme 5-lipoxygenase (5-LOX), responsible for the biosynthesis of pro-inflammatory leukotrienes from arachidonic acid. This leads to a decrease in the production of leukotriene B4 (LTB4), a known mediator of neutrophil chemotaxis, and inhibition of the inflammatory reaction without the participation of the cyclooxygenase pathway (COX-1/COX-2). Thus, an anti-inflammatory effect is provided with minimal impact on gastroprotective prostaglandins.

References: https://www.ncbi.nlm.nih.gov/p...; https://pubmed.ncbi.nlm.nih.go...

At the level of cellular signaling response, boswellic acids modulate the activity of the transcription factor NF-κB, preventing its translocation into the cell nucleus and, as a result, suppressing the expression of genes encoding pro-inflammatory cytokines (including TNF-α, IL-1β, and IL-6), adhesion molecules (ICAM-1, VCAM-1), and metalloproteinases (MMP-9). Simultaneously, a decrease in the activation of the MAPK cascade, especially p38 MAPK, associated with cytokine production and apoptosis regulation, is observed.

References: https://www.sciencedirect.com/...; https://www.tandfonline.com/do...

Inhibition of macrophage and neutrophil activation is accompanied by stabilization of lysosomal membranes and a decrease in the release of pro-inflammatory enzymes such as myeloperoxidase, elastase, and β-glucuronidase. It has been established that boswellic acids suppress the expression of receptors for Toll-like structures (TLR2, TLR4), which additionally limits the activation of the innate immune response and reduces the production of pro-inflammatory interleukins in innate immune cells.

References: https://www.ncbi.nlm.nih.gov/p...; https://link.springer.com/arti...

Antioxidant properties are realized by inhibiting lipid peroxidation and restoring the activity of antioxidant defense enzymes, such as superoxide dismutase, catalase, and glutathione peroxidase. Boswellic acids reduce the level of malondialdehyde (MDA), which is a biomarker of oxidative damage to cell membranes. This provides protection of the endothelium and cells of parenchymal organs from the damaging effects of reactive oxygen species.

References: https://www.mdpi.com/1420-3049...; https://www.sciencedirect.com/...

In the area of modulation of angiogenesis and tissue remodeling, inhibition of VEGF-dependent proliferation of endothelial cells has been recorded, as well as inhibition of MMP-2 and MMP-9 activity, which are involved in the degradation of the basement membrane and migration of vascular cells. This action is associated with a possible anti-angiogenic potential at the level of pathologically active vascular zones. In addition, boswellic acids demonstrate the ability to reduce the expression of growth factors, including TGF-β and IGF-1, which is manifested in the slowing down of cell proliferation and fibrosis processes.

References: https://www.sciencedirect.com/...; https://www.tandfonline.com/do...

Thus, the mechanism of action of Boswellia serrata covers key targets of the inflammatory, immune, antioxidant, and angiogenic cascade. The effects are realized mainly through inhibition of enzyme systems, modulation of the cytokine profile, stabilization of cell membranes, and limitation of free radical reactions. This is confirmed by multi-profile data from in vitro, in vivo, and molecular modeling pharmacological studies.

Synergy — Boswellia serrata

The pharmacological synergy of Boswellia serrata with other biologically active substances has been confirmed by preclinical and clinical studies. It has been established that in combination with flavonoid compounds (for example, quercetin, rutin, luteolin), potentiation of antioxidant action is noted due to the synchronous inhibition of lipid peroxidation, enhancement of antioxidant defense enzyme activity (catalase, glutathione peroxidase), and a decrease in free radical levels in plasma and tissues. This interaction is additive or potentiating in nature and manifests at the systemic level.

The combined use of Boswellia serrata with curcumin is characterized by pronounced potentiation of anti-inflammatory action. The two substances demonstrate a modulating effect on the NF-κB and MAPK signaling cascades, inhibiting the transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and mediators (PGE2, NO). Synergism is also manifested in enhanced inhibition of 5-lipoxygenase and cyclooxygenase-2 activity, which forms a multi-enzyme suppression of the inflammatory cascade. The effect has been recorded at both systemic and tissue levels of interaction, including the gastrointestinal mucosa and joint tissues.

Combination with glycyrrhizic acid (Glycyrrhiza glabra) demonstrates a protective and modulating effect aimed at reducing the irritating effect of boswellic acids on mucous membranes with oral administration. An enhancement of the anti-exudative and membrane-stabilizing action is also observed due to the suppression of mast cell and neutrophil degranulation. These interactions are due to the combined stabilization of cell membranes and inhibition of the release of histamine and leukotrienes.

Of interest is synergism with salicylate-containing plant extracts, such as Salix alba bark and Filipendula ulmaria extract. With combined use, enhanced inhibition of inflammatory mediators at the level of the COX/LOX cascade is observed, as well as an additive effect on pain sensitivity and vascular permeability. This interaction can be considered as functionally complementary and tissue-specific.

In combination with omega-3 polyunsaturated fatty acids, in particular eicosapentaenoic and docosahexaenoic acid, enhancement of angiostatic and antiproliferative effects is noted. Synergy is achieved through simultaneous suppression of VEGF-dependent expression and a decrease in MMP-2/9 activity, which has been confirmed in in vitro and in vivo angiogenesis models. This effect is manifested mainly at the level of the vascular endothelium and tumor microenvironments.

Interaction with selenium-containing compounds and coenzyme Q10 enhances mitochondrial stabilization and energy protection of cells. This is accompanied by a decrease in oxidative stress levels and normalization of cytochrome c-reductase activity, as well as regulation of apoptosis in tissues undergoing chronic damage.

Thus, the synergistic potential of Boswellia serrata has been confirmed in combination with various classes of biologically active substances, including flavonoids, terpenoids, fatty acids, and phenolic acids. The main directions of synergy are potentiation of anti-inflammatory and antioxidant action, regulation of vascular and immune reactions, protection of mucous membranes, and stabilization of mitochondrial and cell membranes.

References:
https://www.ncbi.nlm.nih.gov/p...
https://pubmed.ncbi.nlm.nih.go...
https://www.sciencedirect.com/...
https://link.springer.com/arti...
https://www.tandfonline.com/do...

Geography of Use and Traditional Medicine — Boswellia serrata

Boswellia serrata is traditionally used in the Indian subcontinent, including India, Sri Lanka, Nepal, and Pakistan, as well as in some regions of Southeast Asia. The deepest traditions of its use are recorded in the Ayurvedic medicine system, where the resin of this tree is known as "salai guggul" and is valued as a fragrant, cleansing, and restorative substance. The first written references date back to the treatises "Charaka Samhita" and "Sushruta Samhita" (1st millennium BC), which describe the use of resin in the form of powders, oils, and pastes used for rubbing, smoking, cauterization, and preparation of rubs.

In Indian village traditions, Boswellia serrata was also used as a repellent and cleansing substance in homes and sanctuaries — its resin was placed on smoldering coals for aromatization, expulsion of "evil spirits," and incense during ablutions, weddings, and funeral rituals. Among Bengalis and Tamils, incense of boswellia was considered a ritual that cleanses the space after quarrels, illness, or death. In some tribes of central India, boswellia powder was mixed into wraps made of tree bark or applied to the skin together with buffalo fat. In the Siddha and Unani systems, the use of boswellia as an element of cleansing oil formulas has also been noted.

In Nepal and northern India, boswellia resin was part of compositions for smoking in ritual contexts, along with camphor, myrrh, and sandalwood. In the tradition of Rajasthani nomads, it was burned in front of the entrance to a dwelling or livestock premises, believing that the aroma repels snakes and desert spirits. In Marathi culture, boswellia was used as an ingredient for incense used in temples during morning offerings.

Ethnic groups inhabiting the Eastern Ghats and Aravalli hills (for example, the Gond, Mundari, and Bagha tribes) used Boswellia serrata resin in the form of a dense paste or powder mixed with ash, which was used externally on the skin and in fumigation during witchcraft influences. In some communities, it was believed that incense of boswellia contributes to the "separation of pain" from the body, and also protects the child from the evil eye. The use of resin as a protective agent in children's amulets and protective pendants is mentioned in the regional folklore of Madhya Pradesh.

Outside India, in Sri Lanka and Bangladesh, boswellia was used to a lesser extent medically, but had significance in temple practices. In the Theravada Buddhist tradition, the resin was used to purify the space before meditation or as an offering to the spirits of the earth. In southern Thailand and Cambodia, incense of boswellia was found as an element of borrowed Indian practices during temple festivals and veneration of guardian spirits.

Thus, Boswellia serrata is deeply rooted in the medical, ritual, and domestic practices of the peoples of South Asia, where its resin is revered as an aromatic and protective agent. Historically, it was not only used for medicinal purposes but also occupied a significant place in cult and purification rituals, forming a stable ethnocultural tradition.